Press Releases-SINOVAC: Supply Vaccines to Eliminate Human Diseases-page2

2023/08/28

Sinovac Announces Change of Legal Representative of Sinovac Beijing

BEIJING, China, August 28 2023 /Business Wire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that the C

2023/08/15

SINOVAC Reports Unaudited First Half of 2023 Financial Results

BEIJING, China, August 15, 2023 /Business Wire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaud

2023/07/28

SINOVAC Expands Strategic Partnership with Bio Farma, Bolstering Indonesia's Vaccine Supply

July 28, 2023, Beijing, China – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced a streng

2023/06/30

SINOVAC's Healive^® Maintains Three-Decade-Long Immunity in 15-Year Study

June 30, 2023, Beijing, China – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced promisin

2023/06/05

SINOVAC Named BogotáBio Exclusive Partner, Fueling New Vaccine Advances in Colombia

June 5, 2023, Beijing, China – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced it has be

2023/05/29

SINOVAC Addresses COVID-19 Mutations with Broad-Spectrum Neutralizing Antibody Products: SA55 Injection and Nasal Spray Approved for Clinical Trial in China

May 29, 2023, Beijing, China – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced its Anti-COVID-

2023/05/01

SINOVAC Reports Unaudited Second Half of 2022 Financial Results and Files 2022 Annual Report on Form 20-F

Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, has filed its 2022 annual report on Form 20-F with the U

2023/04/10

SINOVAC Launches New Influenza Vaccine Production Facility

Plant will expand worldwide flu vaccine capacity while setting leading standards for quality and sustainabilityApril 10, 2023, Beijing, China – Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider o

2023/02/21

SINOVAC's Hepatitis A Vaccine Healive^® Approved for Use in Egypt

February 21, 2023, Beijing, China – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced its

2023/02/08

SINOVAC's Hepatitis A Vaccine Healive^® Approved in Kyrgyzstan

February 8, 2023, Beijing, China – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that its in

2023/02/03

SINOVAC Provides Vaccines to Step Up Preventative Healthcare for Children in Turkey

Company's Overseas Delivery of Varicella Vaccine and Approval to Expand Use of CoronaVac Will Help Turkish Minors Combat Infectious DiseasesFebruary 3, 2023, Beijing -- Sinovac Biotech Ltd. ("

2023/01/12

SINOVAC's Hepatitis A Vaccine Healive^® Approved in Lebanon

January 12, 2023, Beijing, China – January 12, 2023, Beijing, China – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical produ

2023/01/06

Study Proves the Immunogenicity and Safety of Co-administration with SINOVAC's WHO Prequalified Varicella and Hepatitis A Vaccines to 1 Year Old

January 6, 2023, Beijing -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that a recen

2022/12/29